Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: A randomised multicentre study comparing two different protocols

Thorax

Volumn 67, Issue 10, 2012, Pages 853-859

  Taccetti, Giovanni ^a   Bianchini, Elisa ^b   Cariani, Lisa ^c   Buzzetti, Roberto ^d   Costantini, Diana ^c   Trevisan, Francesca ^a   Zavataro, Lucia ^a   Campana, Silvia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; COLISTIN; TOBRAMYCIN;

AGE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STENOTROPHOMONAS MALTOPHILIA; VOMITING; WHEEZING;

EID: 84866061431     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-200832     Document Type: Article

References (35)

1. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009;(4):CD004197.
2. Döring G, Høiby N; Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67-91.
3. The UK Cystic Fibrosis Trust Infection Control Group. Pseudomonas aeruginosa Infection in People with Cystic Fibrosis. Suggestions for Prevention and Infection Control. 2nd edn. Bromley, UK: Cystic Fibrosis Trust, 2004.
4. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5. (Pubitemid 27225208)
5. Steinkamp G, Tümmler B, Malottke R, et al. Treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Arch Dis Child 1989;64:1022-8.
6. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-6.
7. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998; 25:88-92. (Pubitemid 28110583)
8. Munck A, Bonacorsi S, Mariani-Kurkdjan P, et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001;32:288-92. (Pubitemid 32938877)
9. Ratjen F, Döring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358:983-4. (Pubitemid 32913526)
10. Ratjen F, Munck A, Kho P, et al ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65:286-91.
11. Griese M, Muller I, Reinhard D. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Eur J Med Res 2002; 7:79-80.
12. Taccetti G, Campana S, Festini F, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005;26:458-61. (Pubitemid 41264209)
13. Nixon GM, Armstrong D, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704. (Pubitemid 32417671)
14. Proesmans M, Boulanger L, Vermeulen F, et al. Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin/ciprofloxacin. J Cyst Fibros 2008;7(Suppl 2):S64.
15. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-9. (Pubitemid 36801771)
16. Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009;33:305-11.
17. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011;165:847-56.
18. Elborn JS, Hodson M, Bertram C. Implementation of European standards of care for cystic fibrosis - control and treatment of infection. J Cyst Fibros 2009;8:211-17.
19. Saiman L, Siegel J; Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003;31(3 Suppl):S1-62.
20. Syrmis MW, O'Carroll MR, Sloots TP, et al. Rapid genotyping of Pseudomonas aeruginosa isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive-element-based PCR assays. J Med Microbiol 2004; 53:1089-96. (Pubitemid 40052490)
21. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38. (Pubitemid 41079078)
22. Saiman L, Marshall BC, Mayer-Hamblett N, et al Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56. (Pubitemid 37430625)
23. Lee TW, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003;2:29-34. (Pubitemid 36857407)
24. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Ann Intern Med 2010;152:726-32.
25. Ho SA, Lee TW, Denton M, et al. Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism. J Cyst Fibros 2009;8:43-6.
26. Macdonald D, Cuthbertson L, Doherty C, et al. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified? J Antimicrob Chemother 2010;65:2373-5.
27. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008;7:523-30.
28. Schelstraete P, Deschaght P, Van Simaey L, et al. Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients. J Cyst Fibros 2010;9:99-103.
29. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-64.
30. Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J Cyst Fibros 2006;5:261-3. (Pubitemid 44824863)
31. Goss CH, Mayer-Hamblett N, Aitken ML, et al. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004;59:955-9. (Pubitemid 39490780)
32. Dalbøge CS, Hansen CR, Pressler T, et al. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J Cyst Fibros 2011;10:318-25.
33. Graff GR, Burns JL. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002;121:1754-60. (Pubitemid 34634392)
34. Denton M, Rajgopal A, Mooney L, et al. Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis. J Hosp Infect 2003;55:180-3. (Pubitemid 37554907)
35. McPherson H, Rosenthal M, Bush A. Can mucoid Pseudomonas aeruginosa be eradicated in children with cystic fibrosis? Pediatr Pulmonol 2010;45:566-8.